Description of the study population; immigrant close contacts with a tuberculin skin test (TST) result ≥5 mm
| Total | 339 (100) |
| Sex | |
| Male | 189 (55.8) |
| Female | 147 (43.4) |
| Unknown | 3 (0.9) |
| Age yrs | |
| 16–24 | 53 (15.6) |
| 25–34 | 80 (23.6) |
| 35–44 | 115 (33.9) |
| ≥45 | 91 (26.8) |
| Continent of birth | |
| Europe, North America | 27 (8.0) |
| South America | 27 (8.0) |
| Asia | 123 (36.3) |
| Other Africa | 98 (28.9) |
| Sub-Saharan Africa | 59 (17.4) |
| Unknown | 5 (1.5) |
| Recent close contact | |
| Non-household contact | 185 (54.6) |
| Household contact | 115 (33.9) |
| Unknown | 39 (11.5) |
| BCG scar | |
| Yes | 274 (80.8) |
| No | 43 (12.7) |
| Unknown | 22 (6.5) |
| QFT-GIT result | |
| Negative | 149 (44.0) |
| Positive | 178 (52.5) |
| Not done | 12 (3.5) |
| T-SPOT.TB® result | |
| Negative | 118 (34.8) |
| Positive | 181 (53.4) |
| Not done/no valid result# | 40 (11.8) |
| TST result mm | |
| 5–9 | 51 (15.0) |
| 10–14 | 87 (25.7) |
| ≥15 | 184 (54.3) |
| Known TST responder | 17 (5.0) |
Data are presented as n (%). BCG: bacille Calmette–Guérin; QFT-GIT: QuantiFERON TB® Gold In-tube. #: no T-SPOT.TB® result because of blood collection failure (n = 12), technical failure (n = 4), inconclusive test results (n = 5) or insufficient blood collected to perform the test (n = 19). QFT-GIT is manufactured by Cellesis, Carnegie, Australia; T-SPOT.TB® is manufactured by Oxford Immunotec, Abingdon, UK.